Reviva Pharmaceuticals Holdings, Inc.NASDAQ:RVPH
- LAST PRICE4.3600
- TODAY'S CHANGE (%)-0.0500 (-1.1338%)
- Bid / Lots4.2500/ 1
- Ask / Lots4.4200/ 2
- Open / Previous Close4.4800 / 4.4100
- Day Range
- 52 Week Range
- Volume71,596
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | RVPH |
|---|---|---|
| 09:32 ET | 2215 | 4.48 |
| 09:39 ET | 100 | 4.41 |
| 09:42 ET | 1017 | 4.41 |
| 09:50 ET | 400 | 4.42 |
| 10:09 ET | 666 | 4.44 |
| 10:15 ET | 600 | 4.4324 |
| 10:18 ET | 710 | 4.44 |
| 10:20 ET | 379 | 4.455 |
| 10:22 ET | 2268 | 4.435 |
| 10:24 ET | 990 | 4.42 |
| 10:26 ET | 1342 | 4.4 |
| 10:29 ET | 600 | 4.4299 |
| 10:36 ET | 195 | 4.4256 |
| 10:49 ET | 600 | 4.43 |
| 10:51 ET | 700 | 4.43 |
| 10:54 ET | 2500 | 4.4883 |
| 10:56 ET | 500 | 4.4401 |
| 10:58 ET | 100 | 4.43 |
| 11:09 ET | 5080 | 4.43 |
| 11:14 ET | 1500 | 4.4536 |
| 11:20 ET | 500 | 4.43 |
| 11:21 ET | 300 | 4.4188 |
| 11:25 ET | 401 | 4.4 |
| 11:27 ET | 452 | 4.4 |
| 11:30 ET | 798 | 4.43 |
| 11:34 ET | 100 | 4.425 |
| 11:38 ET | 300 | 4.42 |
| 11:39 ET | 1910 | 4.4 |
| 11:57 ET | 100 | 4.41 |
| 12:08 ET | 151 | 4.4212 |
| 12:14 ET | 273 | 4.42 |
| 12:17 ET | 300 | 4.4054 |
| 12:26 ET | 100 | 4.45 |
| 12:39 ET | 100 | 4.45 |
| 12:44 ET | 1066 | 4.47 |
| 12:46 ET | 100 | 4.5 |
| 12:51 ET | 700 | 4.4664 |
| 12:53 ET | 100 | 4.47 |
| 01:00 ET | 4693 | 4.4 |
| 01:02 ET | 500 | 4.4299 |
| 01:04 ET | 100 | 4.43 |
| 01:13 ET | 3650 | 4.35 |
| 01:27 ET | 400 | 4.31 |
| 01:29 ET | 250 | 4.34 |
| 01:31 ET | 100 | 4.4 |
| 01:40 ET | 200 | 4.39 |
| 01:51 ET | 250 | 4.39 |
| 02:09 ET | 100 | 4.34 |
| 02:18 ET | 500 | 4.34 |
| 02:32 ET | 101 | 4.275 |
| 02:34 ET | 100 | 4.2762 |
| 02:36 ET | 700 | 4.305 |
| 02:39 ET | 1100 | 4.28 |
| 02:43 ET | 100 | 4.315 |
| 02:59 ET | 11384 | 4.4 |
| 03:14 ET | 350 | 4.3113 |
| 03:21 ET | 100 | 4.42 |
| 03:30 ET | 100 | 4.41 |
| 03:33 ET | 100 | 4.31 |
| 03:39 ET | 1300 | 4.3512 |
| 03:42 ET | 1800 | 4.36 |
| 03:46 ET | 100 | 4.345 |
| 03:50 ET | 950 | 4.3747 |
| 03:53 ET | 1000 | 4.34 |
| 03:55 ET | 250 | 4.352 |
| 03:57 ET | 1000 | 4.3354 |
| 04:00 ET | 500 | 4.36 |
Jan 25, 2023
RedChip CEO Dave Gentry Invited to Join Forbes Business Council, from 8:01AM ET on Wednesday Jan 25, 2023 by Accesswire
8:01AM ET on Wednesday Jan 25, 2023 by Accesswire
Jan 4, 2023
BRIEF-Reviva Pharmaceuticals Announces Letter To Shareholders, from 6:02AM ET on Wednesday Jan 04, 2023 by Thomson Reuters
6:02AM ET on Wednesday Jan 04, 2023 by Thomson ReutersReviva Pharmaceuticals Announces Letter to Shareholders, from 6:00AM ET on Wednesday Jan 04, 2023 by GlobeNewswire
6:00AM ET on Wednesday Jan 04, 2023 by GlobeNewswire
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Reviva Pharmaceuticals Holdings, Inc. | 89.1M | -3.6x | --- |
Longboard Pharmaceuticals Inc | 89.3M | -2.1x | --- |
Achieve Life Sciences Inc | 88.4M | -1.2x | --- |
Portage Biotech Inc | 87.7M | -5.2x | --- |
NuCana PLC | 73.6M | -1.9x | --- |
Lyra Therapeutics Inc | 85.0M | -1.2x | --- |
Company Information
Reviva Pharmaceuticals Holdings, Inc. is a clinical-stage biopharmaceutical company. The Company discovers, develops and seeks to commercialize therapeutics for diseases representing significant unmet medical needs. The Company’s pipeline is focused on the central nervous system, respiratory and metabolic diseases. The Company’s pipeline has two drug candidates, RP5063 (brilaroxazine) and RP1208. Its lead drug candidate, RP5063, is ready for continued clinical development for multiple neuropsychiatric indications. These include schizophrenia, bipolar disorder (BD), major depressive disorder (MDD), attention-deficit/hyperactivity disorder (ADHD), behavioral and psychotic symptoms of dementia or Alzheimer’s disease (BPSD), and Parkinson’s disease psychosis. Furthermore, RP5063 is also ready for clinical development for two respiratory indications, pulmonary arterial hypertension (PAH) and idiopathic pulmonary fibrosis (IPF). Its RP1208 drug candidate is a triple reuptake inhibitor (TRI).
Contact Information
- Headquarters
- 19925 Stevens Creek Blvd., Suite 100CUPERTINO, CA, United States 95014
- Phone
- 408-501-8881
- Fax
- 408-904-6270
Executives
- Independent Chairman of the Board
- Parag Saxena
- President, Chief Executive Officer, Director
- Laxminarayan Bhat
- Chief Financial Officer
- Narayan Prabhu
- Independent Director
- Leslie Funtleyder
- Independent Director
- Richard Margolin
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $89.1M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 20.4M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.08 |
EPS | $-1.22 |
Book Value | $1.99 |
P/E Ratio | -3.6x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
